Showing items 1 - 2 of 2

Final 10-year results of the Breast International Group 2–98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer

- Sonnenblick, Amir, Francis, Prudence A., Lluch, Ana, Gnant, Michael, Goldhirsch, Aron, Di Leo, Angelo, Barnadas, Agusti, Cortes-Funes, Hernan, Piccart, Martine, Crown, John, Azim Jr, Hatem A., de Azambuja, Evandro, Nordenskjold, Bo, Gutierez, Jorge, Quinaux, Emmanuel, Mastropasqua, Mauro G., Ameye, Lieveke, Anderson, Michael

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial

- Fernández-Cuesta, Lynnette, Oakman, Catherine, Larsimont, Denis, Francis, Prudence A., Crown, John, Piccart-Gebhart, Martine, Viale, Giuseppe, Leo, Angelo Di, Olivier, Magali, Falagan-Lotsch, Patricia, Smoth, Ke-seay, Quinaux, Emmanuel, Buyse, Marc, Dolci, M. Stella, Azambuja, Evandro De, Hainaut, Pierre, Dell'Orto, Patrizia

  • 1
  • Disclaimer
  • Privacy
  • Copyright
  • Contact
  • Deposit